Reprint
Novel Challenges and Therapeutic Options for Liver Diseases
Edited by
June 2024
182 pages
- ISBN978-3-7258-1528-9 (Hardback)
- ISBN978-3-7258-1527-2 (PDF)
This book is a reprint of the Special Issue Novel Challenges and Therapeutic Options for Liver Diseases that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
This Special Issue focuses on cutting-edge developments, from viral diseases via autoimmune, vascular, metabolic disorders, to liver cirrhosis and its complications, such as acute and chronic hepatic failure and the development of primary liver cell carcinoma. Digitalization, prevention, and telemedicine are also included. Finally, this Special Issue gives new insights in future translational hepatology.
Format
- Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
microbiome; obesity; metabolic syndrome; fecal microbiota transplantation; ROTEM®; TIPS; liver disease; thrombosis risk assessment; hypercoagulable state; portal hypertension; hepatic decompensation; chronic hepatitis B; chronic hepatitis C; chronic hepatitis D; antiviral therapy; liver cirrhosis; DAA therapy; functional cure; HBsAg loss; hepatology; liver cirrhosis; liver transplantation; decompensated cirrhosis; acute-on-chronic liver failure; NASH; pNRF2; SOCS3; immunohistochemistry; liver disease; NASH; UDCA; bile acid transporter; ALT; GGT; TE; neuroendocrine; transplantation; outcomes; liver metastases; systematic review; liver disease; hepatology; prevention; management; telemedicine; metabolic dysfunction-associated fatty liver disease; monitor; lifestyle modification; COVID-19 pandemic; chronic hepatitis B; NUC treatment; low-level HBsAg carriers; therapeutic vaccination; third generation pre-S/S vaccine; long-term observation; hepatocellular carcinoma; HCC; MASLD; MASH; NAFLD; NASH; biomarker; intestinal microbiota; chronic hepatitis b; HBsAg seroconversion; seroclearance; hepatocellular carcinoma; history of hepatology; MASLD/NAFLD; liver fibrosis/cirrhosis; chronic viral hepatitides; liver transplantation; liver–microbiome axis; organokine crosstalk; chronobiology; liver aging